Comparing Two Chemotherapy Schedules for Colorectal Cancer That Has Spread
Compares two dosing schedules of FOLFIRI chemotherapy in adults with metastatic colorectal cancer.
Key facts
- Who runs it
- University Of Pecs
- Where
- Pécs, HungarySee the site
- Trial code
- Registry title
- Impact of Biweekly and Triweekly Dosing Regimens
- Status
- Not yet recruiting
- Phase
- Phase 2
- People taking part
- 56 people, planned
- Started
- 1 Jul 2025
- Expected to end
- 1 Jul 2031
- Type of study
- Interventional
- Record updated
- 18 July 2025
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with colorectal cancer that has spread, who have not yet had drug treatment for the spread and cannot or will not take targeted biological therapy. It compares FOLFIRI chemotherapy given every 2 weeks with every 3 weeks.
- Age
- 18 years or older, no upper age limit.
- Sex
- All sexes can join.
- Disease stage
- Colorectal adenocarcinoma that has spread (metastatic), proven by tissue examination, and measurable on scans (RECIST 1.1). ECOG performance score 0-2. Life expectancy of at least 3 months.
- Earlier treatment
- No earlier drug treatment for the spread disease. Adjuvant treatment finished more than 6 months ago is allowed. No other cancer treatment within 4 weeks before starting.
- Biomarker or test result
- The tumour sample must have molecular testing (RAS/RAF status and MSI status). Tumours with MSI-H cannot join if immunotherapy is possible.
Main reasons for not taking part
- Known complete DPD deficiency or UGT1A1 polymorphism
- Allergic reaction to the study drugs in the past
- Needs surgery-preparing (conversion) treatment or fast tumour shrinkage
- Few metastases where local treatment is planned by the tumour board
- Severe organ problems or serious infection
The registry criteria, word for word
Show all 20 criteriaShow less
Who can take part
- patients aged 18 years or older (no upper age limit)
- patients ineligible for targeted biological therapy (see table 8 in the detailed protocol) or patients who refuse targeted biological therapy
- histologically proven metastatic colorectal adenocarcinoma from the primary tumour
- consent to participate in the study
- ECOG performance score of 0-2
- normal haematological and organ functions (serum AST, GOT, GPT -and creatinine- below three times the upper limit of normal, serum bilirubin is below 5xULN, absolute neutrophil count is > 1,5G/L, platelet count >100 G/L; higher AST/GOT/GPT values are allowed in case of liver metastasis upon the investigator’s decision)
- disease measurable according to RECIST 1.1 and eligibility for delivering CT scan with contrast agents
- use of high efficacy contraception
- life expectancy of at least 3 months as judged by the treating physician
- molecular pathology testing of the tumor specimen (RAS/RAF status + MSI status)
Who cannot take part
- previous systemic treatment for metastatic disease (adjuvant treatment if completed more than 6 months ago is allowed)
- MSI-H tumors if there’s no contraindication to immunotherapy
- patients who are expected to become eligible for targeted biological therapy after a certain period of time, and who receive FOLFIRI alone only at the beginning of the therapeutic sequence (e.g., in the postoperative period), are not eligible to participate in the study (targeted biological therapy administered in a later line of treatment is permitted within the study)
- patients eligible for conversion therapy (systemic treatment preceeding surgical resection of CRC metastases)
- patients requiring rapid regression (preferentially treated with FOLFOX)
- severe organ dysfunction; severe internal or chronic infectious disease excluding oncology treatment; acute, severely symptomatic infectious disease within 2 weeks prior to treatment
- other treatment for oncological purposes within 4 weeks prior to treatment (palliative, decompressive or analgetic radiotherapy is allowed)
- history of hypersensitivity to study agents
- oligometastatic disease where the tumor board indicates ablative local treatment of metastases
- known complete DPD deficiency or UGT1A1 polymorphysm (screening is not part of the study due to access difficulties in routine clinical practice)
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- How many different drug treatment plans (such as chemotherapy) have you had for cancer that has spread?
- Which best describes how well you can look after yourself and be active?
Where in Hungary
- University of Pécs - Clinical Center Institute of OncotherapyPécs, HungaryNot yet recruiting
About the trial
What the trial wants to find out
To compare Progression-Free Survival (PFS) data assessed by the investigator and based on the Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v.1.1) when applying 2weeks (q2w) and 3weeks (q3w) FOLFIRI chemotherapy regimens in the first-line palliative treatment of metastatic colorectal carcinoma
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record
Print a page for my doctorData and sources
- Registry record
- Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
- Official title
- Impact of Biweekly and Triweekly Dosing Regimens on Progression-Free Survival in First-Line FOLFIRI Treatment of Metastatic Colorectal Cancer: A Non-Inferiority Study (FIR-DIR)
- Plain-language title
- Comparing Two Chemotherapy Schedules for Colorectal Cancer That Has SpreadGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 9 November 2026.
- Fit questions
- Built from 2025-522305-38-00, who can take part
- Record updated
- 18 July 2025